



Curriculum vitae Europass



PERSONAL INFORMATION

NAME **Andor Minodora**

Adress Timișoara, România

Telefon

Mobil:
+40722397507

E-mail andor.minodora@umft.ro

Sex Feminin

Occupational field Cardiology, Internal medicine, Medical Semiotics, Heart Failure,
Prevention of Cardiovascular diseases

Profesional experience

Actual position

March 2022 – present - Assistant Professor at University of Medicine and
Pharmacy Victor Babes Timisoara
Medical Semiotics Dept.

2011-pres – Senior Cardiologist – City Hospital Timisoara

2008-pres – Senior in Internal Medicine – City Hospital Timisoara

Past Position	March 2012- 2022– Lecturer at University of Medicine and Pharmacy Victor Babes Timisoara Medical Semiotics Dept.
	1998-2012– University assistant - University of Medicine and Pharmacy Victor Babes Timisoara Medical Semiotics Dept.
	2002-2006 – Specialist in Internal Medicine – Medicali’s Private Clinical Center
	1997-2002 – Resident in Internal Medicine – City Hospital Timisoara

Education and development

Period	. 2011 - prezent
Calification	Medical Doctor Specialist cardiology
Field and Skills	Cardiology
Institution	Oct Universitatea de Medicină și Farmacie “Victor Babeș” Timișoara
Level of education	Medical speciality

Period	Feb.2007 - Oct.2011
Calification	Resident cardiology, 2nd speciality
Field and Skills	Cardiology skills as requierd by the Health Minister
Institution	Institutul de Boli Cardiovasculare Timisoara
Level of education	Medical speciality

Period	June 2008 - present
Calification	Senior Medical Doctor in Internal Medicine
Field and Skills	Internal Medicine
Institution	University of Medicine and Pharnacy „Victor Babeș” Timișoara
Level of education	Medical speciality

Period	March 2003 – june 2008
Calification	Specialist in Internal Medicine
Field and Skills	Internal Medicine
Institution	University of Medicine and Pharnacy „Victor Babeș” Timișoara
Level of education	Medical speciality

Period	Iun.2003
Calification	General Echography
Field and Skills	Performing general ultrasound

Institution University of Medicine and Pharmacy „Victor Babeş” Timişoara
Level of education Medical skill

Period Iun.2004

Calification **Cardiac echography**

Field and Skills University of Medicine and Pharmacy „Victor Babeş” Timişoara

Institution Medical skill

Period Apr 2010

Calification **Vascular echography**

Field and Skills Vascular echography

Institution University of Medicine Babes-Bolyai Cluj

Level of education Medical skill

Period Nov.2000 - Nov.2005

Calification **PhD. Doctor in Medicine**

Field and Skills University of Medicine and Pharmacy „Victor Babeş” Timişoara

Institution ISCDE 6

Period Sep. 1991 – Iun. 1997

Calification **Student / Licence Diploma, Specialization in General Medicine**

Field and Skills Faculty of General Medicine

Institution University of Medicine and Pharmacy „Victor Babeş” Timişoara

2012 – Master in Public Health,
University of Medicine and Pharmacy „Victor Babes” Timisoara

2021 - Habilitation thesis
University of Medicine and Pharmacy „Victor Babes” Timisoara

Participation in scientific and professional associations:

1. Member of the General Assembly of the Romanian College of Physicians - from 2020
2. member of the College of Doctors from Romania - since 1998
3. member of SRIM - Romanian Society of Medical Informatics - since 2003
4. Member Working Group "Heart Failure" of European Society of Cardiology
5. Member of the Working Group "Heart Failure", Romanian Society of Cardiology
6. Member of the Working Group "Ischemic Cardiology", Romanian Society of Cardiology
7. Member of the Working Group "Atherosclerosis and Atherothrombosis", Romanian Society of Cardiology
8. Examination Commission National Competition for the occupation of vacant positions of doctors, specialty Internal Medicine, March 2009
9. Internal Medicine Medical Specialist Exam Commission, session March 5, 2009, March 5, 2008
10. Internal Medicine Medical Specialist Examination Commission, 2008-2012
11. Examination Commission for Medical Specialist/Primary in Family Medicine 2019, 2020, 2021

Participation in scientific events (selection):

- National Cardiology Congress, Sinaia: 1998-2019
- European Cardiology Congress: 2004, 2006, 2008, 2010, 2012, 2014, 2018, 2019
- European Heart Failure Congress: 2008, 2009, 2010
- World Cardiology Congress: 2002
- National Medical Informatics Conference: 1996, 1998, 2002, 2010, 2012
- European Medical Informatics Conference 2006

'Personalizing health care' (H2020-SC1-2016-2017) under the topic: SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population

'BHC 16 - 2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes

EURO-SHOCK under the topic: SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population – June 2021

Per-review at the following magazines:

Clinical Interventions in Aging (Journal Impact Factor: 3.023)
Scientific Research Publishing
JSM Annals of Clinical and Experimental Hypertension

Personal aptitudes and skills

Languages **Romanian – mother tongue**

English – fluently
French – good

Representative papers

1. Radu G, Bordejovic AD, Buda V, Tomescu MC, Dragan I, Dehelean L, Cocos IL, Cheveresan A, **Andor M** Cardiovascular risk factors for different types of psychiatric pathologies. a correlative study, Farmacia. 2020, 1;68(5):835-842. ISSN: 1178-2021.<https://doi.org/10.31925/farmacia.2020.5.9> IF 1.607
2. Buda V, Prelipcean A, **Andor M**, Dehelean L, Dalleur O, Buda S, Spatar L, Mabda MC, Suciu M, Danciu C, Tudor A Potentially Inappropriate Prescriptions in Ambulatory Elderly Patients Living in Rural Areas of Romania Using STOPP/START (Version 2) Criteria Clin Interv Aging. 2020;15:407-4017. ISSN:1178-1998.<https://doi.org/10.2147/CIA.S233270> IF 3.023
3. **Andor M**, Dehelean L, Romosan AM, Buda V, Radu G, Caruntu F, Bordejovic A, Manea MM, Papava I, Bredicean CA, Romosan RS, A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication Neuropsychiatr Dis Treat, 2019, 15, 349–355. ISSN: 1178-202, DOI: [10.2147/ndt.s186892](https://doi.org/10.2147/ndt.s186892) IF 2.157
4. Buda V, **Andor M**, Baibata DE, Cozla R, Radu G, Coricovac D, Danciu C, Ledeti I, Cheveresan A, Nica C, Tuduce P, Tomescu MC. Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. *Drug Des Devel Ther.* 2019;13:1915-1925 <https://doi.org/10.2147/DDDT.S186378> IF 3.216
5. Dehelean L, Marinescu I, Stovicek PO, **Andor M**. Cardiovascular anomalies and evolutionary risk factors in schizophrenia—multifactorial approach Rom J Morphol Embryol. 2019, 60(4):1105-1113. ISSN: 2066-8279<https://rjme.ro/RJME/resources/files/60041911051113.pdf> 1.411
6. Buda V, **Andor M**, Cristescu C, Tomescu MC, Muntean DM, Bâibăță DE, Bordejovic DA, Danciu C, Dalleur O, Coricovac D, Crainiceanu Z, Tudor A, Ledeti I, Petrescu L Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril. *Drug Des Devel Ther.* 2019;13:3515-3526 <https://doi.org/10.2147/DDDT.S218428> IF 3.216
7. Buda, V., **Andor, M.**, Cristescu, C. et al. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension *Ir J Med Sci* **186**, 621–629 (2017). <https://doi.org/10.1007/s11845-017-1580-5> IF 1.100
8. Buda, V.; **Andor, M.**; Petrescu, L.; Cristescu, C.; Baibata, D.E.; Voicu, M.; Munteanu, M.; Citu, I.; Muntean, C.; Cretu, O.; Tomescu, M.C. Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment. *Int. J. Mol. Sci.* **2017**, *18*, 348, DOI: [10.3390/ijms18020348](https://doi.org/10.3390/ijms18020348) IF3.687

9. Buda V, **Andor M**, Ledeti A, et al. Comparative Solid-State Stability of Perindopril Active Substance vs. Pharmaceutical Formulation *Int J Mol Sci.* 2017;18(1):164. Published 2017 Jan 15. [doi:10.3390/ijms18010164](https://doi.org/10.3390/ijms18010164) **3.687**
10. Dehelean L, **Andor M**, Romosan AM, Manea MM, Romosan RS, Papava I, Bredicean AC, Buda VO, Tomescu MC, Pharmacological and Disorder Associated Cardiovascular Changes in Patients with Psychosis. A Comparison between Olanzapine and Risperidone Farmacia 2018, 66(1):129-134. ISSN: 0014-8237, <http://www.revistafarmacia.ro/201801/issue12018art17.html> IF **1.527**

Experience in clinical trials:

Co-Investigator:

1. 1999-2002 – Heart failure study phase II
2. 1999-2000 – Acute coronary syndrome, study phase II
3. 2007-2008 –Acute pneumonia, study phase II
4. 2007-2007 - Atrial fibrillation, study phase II
5. 2003-2003 – Joints diseases, study phase III
6. 2004-2006 – Chronic heart failure, study phase III
7. 2006-prez – Heart failure study phase III
8. 2007-prez – Prevention of the embolic diseases, study phase III
9. 2007-2008 – Arterial hypertension, study phase III
10. 2006-2007 – Heart failure with renal failure, studt phase III
11. 2008-2008 – Alpha blocker therapy, study phase I
12. 2008-2008 – Bronchial asthma, study phase III
13. 2008-2010 – Renal failure, anemia, study phase III
14. 2009-prez- Atrial fibrillation, study phase II
15. 2009-2010- Arterial hypertension, study phase III
16. 2018-2020 - ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI

Principal Investigator:

1. 2004-2004 – Pain therapy, study phase III
2. 2008-prez – Liver cirrhosis, study phase II
3. 2009-2010 – Rheumatoid arthritis, study phase III
4. 2010-2020- Hypercholesterolemia, studies phase III
5. 2009-2014 - Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
6. 2014-2017 - Sacubitril/valsartan in heart failure with preserved ejection fraction
7. 2023-pres - Obesity or Overweight with Weight Related Comorbidities